tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Satellos Bioscience Announces Positive Phase 1b Results and Upcoming Clinical Trials for DMD

Story Highlights
Satellos Bioscience Announces Positive Phase 1b Results and Upcoming Clinical Trials for DMD

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Satellos Bioscience ( (TSE:MSCL) ) has provided an announcement.

Satellos Bioscience reported positive results from its Phase 1b study of SAT-3247 in adults with Duchenne muscular dystrophy, demonstrating safety and improved grip strength. The company plans to initiate a follow-up study and a global Phase 2 trial in children with DMD. Financially, Satellos ended Q2 2025 with $52.1 million in cash, experiencing a net loss due to increased R&D and administrative expenses.

The most recent analyst rating on (TSE:MSCL) stock is a Buy with a C$1.20 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page.

Spark’s Take on TSE:MSCL Stock

According to Spark, TipRanks’ AI Analyst, TSE:MSCL is a Neutral.

Satellos Bioscience faces challenges typical of early-stage biotech companies, including no revenue and reliance on financing to sustain operations. Technical indicators suggest a bearish momentum. However, positive corporate developments, such as clinical trial progress and increased financing, provide a potential upside if successful commercialization ensues.

To see Spark’s full report on TSE:MSCL stock, click here.

More about Satellos Bioscience

Satellos Bioscience Inc. is a clinical-stage biotechnology company focused on developing life-improving medicines to treat degenerative muscle diseases. The company is working on innovative treatments, such as SAT-3247, aimed at rebuilding muscle and improving strength, particularly for conditions like Duchenne muscular dystrophy (DMD).

Average Trading Volume: 151,867

Technical Sentiment Signal: Sell

Current Market Cap: C$105.8M

For an in-depth examination of MSCL stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1